Results 231 to 240 of about 7,603,377 (331)
A Pathology of Medical Ethics: Economic Medical Rationing in a Morally Incoherent Society [PDF]
Jones, L. Gregory
core +1 more source
ABSTRACT Objective To evaluate the long‐term impact of early intensive treatment (EIT) versus escalation (ESC) strategies using high‐efficacy disease‐modifying therapies (HE‐DMTs) on disability progression in relapsing multiple sclerosis (RMS). Methods This observational study included 4878 RMS patients from the Italian Multiple Sclerosis Register ...
Pietro Iaffaldano+47 more
wiley +1 more source
Advancing artificial intelligence ethics in health and genomics: lessons from a public survey in South Korea. [PDF]
Lee J, Yoo W, Kim H.
europepmc +1 more source
ABSTRACT Objective Spinal muscular atrophy (SMA) significantly impacts motor function. This study aimed to assess the persistent burden and unmet needs among currently treated patients with SMA and their caregivers. Methods Two complementary web‐based surveys were distributed in August 2024 among patients with SMA and their caregivers.
Julie A. Parsons+8 more
wiley +1 more source
Experiences of internship nursing students in confronting ethical issues: a qualitative study. [PDF]
Heidari T+3 more
europepmc +1 more source
Identification of Dementia With Lewy Bodies by Skin Biopsy in Recent‐Onset Cognitive Impairment
ABSTRACT Immunofluorescence for phosphorylated alpha‐synuclein in skin biopsy samples is an emerging biomarker in synucleinopathies comprising Dementia with Lewy bodies. In this pilot study, 19 patients with recent‐onset (≤ 18 months) cognitive impairment underwent skin biopsy at baseline, with follow‐up clinical re‐evaluation.
Alessandro Furia+13 more
wiley +1 more source
Medical humanities education in Vietnamese medical schools: a comparative perspective from the USA and Republic of Korea. [PDF]
Dang TKC, Yeh BI.
europepmc +1 more source
The Pope John XXI International Prize for Medical Ethics [PDF]
Laforet, Eugene G.
core +1 more source
Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia+20 more
wiley +1 more source